Abbott offers a patient assistance program for patients who are unable to afford Abbott medications. The website helps patients learn about the program and navigate the application process. Abbott makes Kaletra (lopinavir/ritonavir) and Norvir (ritonavir).

The Boehringer Ingelheim Cares Foundation Patient Assistance Program (BI-PAP) makes Boehringer Ingelheim  products available to patients who are without pharmaceutical insurance coverage and who meet certain household income levels. The website helps patients learn about the program and navigate the application process. Boehringer Ingelheim makes Aptivus (tipranavir) and Viramune (nevirapine).

Bridges to Access, GlaxoSmithKline’s patient assistance program for non-oncology medicines, provides GSK prescription medicines to eligible low-income patients without prescription drug benefits.

Bristol-Myers Squibb has three patient assistance programs for people with HIV: Access Virology, the Atripla Patient Assistance Program, and Together Rx Access. Access Virology and Together Rx Access cover Reyataz (atazanavir) and Sustiva (efavirenz); the Atripla Patient Assistance Program Covers Atripla (efavirenz/emtricitabine/tenofovir).

The Egrifta Patient Assistance Program  provides Egrifta (tesamorelin) for free to uninsured or under-insured patients who earn less than 600 percent of the federal poverty level. For more information, please call the AXIS Center at 877-714-AXIS (2947).

The Genentech Access To Care Foundation provides Fuzeon (enfuvirtide) and Invirase (saquinavir mesylate) free to qualified patients. To enroll, patients must be uninsured and have an annual adjusted gross household income of less than $100,000.

Gilead Sciences provides financial assistance to people with HIV through two programs: the U.S. Advancing Access program and the Atripla Patient Assistance Program. The first program covers Emtriva (emtricitabine), Truvada (emtricitabine/tenofovir), and Viread (tenofovir); the second covers Atripla (efavirenz/emtricitabine/tenofovir). Both programs provide assistance to patients who do not have insurance or are otherwise in need of financial assistance to pay for their HIV medications.

Merck offers a patient assistance program for those who are unable to afford Merck medications. The website helps patients learn about the program and navigate the application process. Merck makes Isentress (raltegravir), which has its own separate program, and Crixivan (indinavir).

Merck offers a special program, called Support, for Isentress (raltegravir). This program helps patients learn about insurance coverage through the reimbursement plan, and provides Isentress free of charge to eligible patients through patient assistance services.

The Partnership for Prescription Assistance (PPA) helps patients without prescription medication coverage to find programs that will help them obtain the medicines they need.